Human engineered heart tissue as a model system for drug testing

A Eder, I Vollert, A Hansen, T Eschenhagen - Advanced drug delivery …, 2016 - Elsevier
A Eder, I Vollert, A Hansen, T Eschenhagen
Advanced drug delivery reviews, 2016Elsevier
Drug development is time-and cost-intensive and, despite extensive efforts, still hampered
by the limited value of current preclinical test systems to predict side effects, including
proarrhythmic and cardiotoxic effects in clinical practice. Part of the problem may be related
to species-dependent differences in cardiomyocyte biology. Therefore, the event of readily
available human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CM) has
raised hopes that this human test bed could improve preclinical safety pharmacology as well …
Abstract
Drug development is time- and cost-intensive and, despite extensive efforts, still hampered by the limited value of current preclinical test systems to predict side effects, including proarrhythmic and cardiotoxic effects in clinical practice. Part of the problem may be related to species-dependent differences in cardiomyocyte biology. Therefore, the event of readily available human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CM) has raised hopes that this human test bed could improve preclinical safety pharmacology as well as drug discovery approaches. However, hiPSC-CM are immature and exhibit peculiarities in terms of ion channel function, gene expression, structural organization and functional responses to drugs that limit their present usefulness. Current efforts are thus directed towards improving hiPSC-CM maturity and high-content readouts. Culturing hiPSC-CM as 3-dimensional engineered heart tissue (EHT) improves CM maturity and anisotropy and, in a 24-well format using silicone racks, enables automated, multiplexed high content readout of contractile function. This review summarizes the principal technology and focuses on advantages and disadvantages of this technology and its potential for preclinical drug screening.
Elsevier